PH KOREA 2026

Overseas Invited Faculty

Chih-Hsin Hsu

National Cheng Kung Univ. Hospital, Taiwan

Chih-Hsin Hsu is a Professor of National Cheng Kung University and serves as deputy superintendent at National Cheng Kung University Hospital. He received his MD degree from China Medical College (Taiwan) , Master's degree on pulmonary vascular disease from University of Bologna (Italy), and PhD from National Cheng Kung University (Taiwan). Chih-Hsin Hsu also serves as President of the Taiwan Society of Critical Care Medicine, Executive Director of the Taiwan Pulmonary Hypertension Association, , Fellow of the European Society of Cardiology (FESC), Fellow of the American College of Cardiology (FACC), and Fellow of the Asian Pacific Society of Cardiology (FAPSC). His research and clinic practice focus on pulmonary hypertension, heart failure and critical care. He was Taiwan Coordinator and PI of several international studies on pulmonary hypertension, including FREEDOM, EXPERT, REPLACE, A Due and Hyperion. He is also as Steering Committee of Taiwan PAH Registry and author of Taiwan PH guideline. He is also active internationally as member or committee member of various esteemed organizations like International Society of Heart Lung Transplant, European Society of Cardiology.

Derek Solum

United Therapeutics, USA

Derek Solum is the Senior Director of Product Development at United Therapeutics, a biotechnology company focused on the creation and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. At United Therapeutics, Derek leads the ralinepag clinical development program including strategy and implementation at all stages. Derek leads and manages large, global, multicenter clinical studies, prepares late-stage clinical study protocols and study reports, supports submission activities for marketing authorization, and provides due diligence support for new expansion activities. Derek received a Bachelor of Science degree in Biology and Chemistry from the University of Utah and a PhD in Molecular Neuroendocrinology from Loyola University Chicago. Subsequently, he completed a postdoctoral fellowship in Molecular Medicine at the University of California, San Diego.

Hiromi Matsubara

NHO Okayama Medical Center, Japan

Hiromi Matsubara, MD, PhD, is currently the Deputy Director of National Hospital Organization Okayama Medical Center, Okayama, Japan. After finishing his fellowship at National Cardiovascular Center, Osaka, Japan in 1993, he became an Assistant Professor of Department of Physiology II at Okayama University Graduate School of Medicine and Dentistry. He became an Assistant Professor of Department of Cardiovascular Medicine in 1997 and the Associate Professor in 2000. He then became the Clinical Professor of Department of Cardiovascular Medicine and the Director of Department of Cardiology at Okayama Medical Center. His investigative interests have focused on clinical and physiologic aspects of pulmonary hypertension. He started balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension in 2004 and has experienced about 3000 procedures of BPA in more than 500 patients during past 22 years. He has made Department of Cardiology at Okayama Medical Center as the largest BPA center in Japan.

John Feenstra

The Wesley Hospital, Australia

Dr John Feenstra is a Thoracic and Pulmonary Hypertension Physician with extensive expertise in the diagnosis and management of pulmonary hypertension. He serves as Director of the Wesley Pulmonary Hypertension Unit, Director of Pulmonary Hypertension Research Queensland, and as the Lead Physician for Pulmonary Hypertension within the Queensland Lung Transplant Service at the Prince Charles Hospital. Dr Feenstra is the current President of the Pulmonary Hypertension Society of Australia and New Zealand, and holds the title of Senior Lecturer at the University of Queensland. He is actively engaged in research, teaching, and clinical trials, contributing to the advancement of pulmonary hypertension care across the region.

Keiko Yamauchi-Takihara

Professor Emeritus, Osaka Univ., Japan

She was a Vice-President of JPCPHS during 2015-2021. She had been working as a Director of Health Care Center, Osaka University and the Professor of Cardiovascular Medicine, Osaka University Graduate School of Medicine. She was appointed as a Vice-President of Osaka University in 2014, and also as a Trustee of National Cerebral and Cardiovascular Center and an Auditor of National Institute for Quantum Science and Technology, Japan. Although she has a longstanding interest in genetics and biological mechanism of the development of cardiomyopathy, her interest also include pulmonary hypertension and cardiopulmonary interrelations from the view point of genetics and inflammation.

Kuo Yang Wang

China Medical Univ. Hospital, Taiwan

Dr. Kuo-Yang Wang, MD, received his Cardiology training in 1980s and continuously served in Taichung Veterans General Hospital till 2018, he also received his post-doctoral fellow-ship at University of Pennsylvania, 1995 to 1997 and attended a 4-weeks master class of Pulmonary Hypertension mentored by Prof. Galie at University of Bologna, 2016. He set up a Pulmonary Hypertension Center at Taichung Veterans GH since 2006, and cared many pulmonary hypertension patients, including primary and secondary causes. He moved to China Medical University Hospital, Taichung, where he leads the Center for Pulmonary Hypertension and Pulmonary Vascular Disease since 2018 and continuously takes care of pulmonary hypertension patients. He established and is the president of Taiwan PH Association (TPHA) since 2016. He is conducting International Pulmonary Hypertension Conference of TPHA (Contemporary Management and Outcomes of Pulmonary Hypertension) twice a year over the past 10 years. He is the co-founder of the EASOPH and organizer of the inaugural EASOPH congress in Taipei in 2019.

Nick H. Kim

UCSD, USA

Nick H. Kim, MD graduated from Harvard University and received his medical doctorate degree from the University of Chicago, Pritzker School of Medicine. He completed internal medicine residency at the University of Chicago and pulmonary and critical care fellowship training at UCSD. Dr. Kim is professor of medicine and section chief of the pulmonary vascular medicine program at UCSD. He specializes in the evaluation and treatment of pulmonary hypertension. Dr. Kim has served as medical director of the pulmonary thromboendarterectomy program since 2012. Dr. Kim also established UCSD's balloon pulmonary angioplasty program in 2015. UCSD is an internationally recognized center for the treatment of all forms of pulmonary hypertension. Dr. Kim has extensive experience with clinical trials design and has served on numerous steering committees in PH. He is widely published in peer reviewed medical journals. Dr. Kim is also involved in training medical students, residents, and fellows. Dr. Kim served as fellowship training program director for 9 years. Dr. Kim is board certified in pulmonary disease and critical care medicine.

Samuel G. Rayner

Univ. of Washington, USA

Dr. Samuel Rayner is an Assistant Professor in the Division of Pulmonary, Critical Care & Sleep Medicine at the University of Washington (UW), Seattle, USA. He specializes in pulmonary vascular disease and serves as Medical Director of the UW Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program and Associate Director of the UW Hereditary Hemorrhagic Telangiectasia (HHT) Center. Dr. Rayner leads an NIH-funded research laboratory focused on in vitro modeling of pulmonary arterial hypertension using microfluidic and vascular bioengineering platforms. He has a particular interest in the interplay between hemodynamic forces and vascular dysfunction, on both a clinical and cellular level.

Shigetoyo Kogaki

Osaka General Medical Center, Japan

Shigetoyo Kogaki M.D. is a director, Department of Pediatrics and Neonatology at the Osaka General Medical Center. He graduated from Osaka University and has had extensive experience in the clinical fields of pediatric pulmonary hypertension, cardiomyopathy, heart failure, and heart and lung transplantation. He belongs to Japanese medical societies including the Japan Pediatric Society, the Japanese Society of Pediatric Cardiology and Cardiac Surgery, and the Japanese Circulation Society. He is a board member of the Japanese Pulmonary Circulation and Pulmonary Hypertension Society and served as the Congress President of the 6th EASOPH Scientific Meeting.

Shozaburo Doi

Institute of Science Tokyo, Japan

Shozaburo Doi is Visiting Professor of Institute of Science Tokyo and Visiting Professor of Tokyo Healthcare University. He started his research career in the field of pulmonary circulation physiology at the Cleveland Clinic Foundation, Ohio in the USA. His long-term research focuses are basic and clinical studies of pulmonary hypertension. He is now honorary fellow of Japanese Society of Pediatric Cardiology and Cardiac Surgery, and honorary fellow of Japanese Pulmonary Circulation and Pulmonary Hypertension Society. He is also Fellow of Japanese Circulation Society (FJCS) and Fellow of Japanese Collage of Circulation (FJCC).

Stephan Rosenkranz

Univ. of Cologne, Germany

Chair, Cologne Cardiovascular Research Center (CCRC). Head of Expert Center on Pulmonary Hypertension, the University of Cologne. Head ("Principal Investigator") of working group on "Molecular Cardiology"; Research focus: Signal transduction and pathobiological relevance of receptor tyrosine kinases in cardiovascular disease.

Takahiro Hiraide

Keio Univ. School of Medicine, Japan

Dr. Takahiro Hiraide graduated from Keio University School of Medicine in 2012 and subsequently completed his residency and clinical training in Internal Medicine at Keio University Hospital. Throughout his career, he has focused on elucidating the molecular mechanisms of pulmonary hypertension, right ventricular dysfunction, cardiac hypertrophy, and vascular diseases. His research has centered on developing novel therapies for pulmonary arterial hypertension (PAH) using gene-editing technologies, and he has published extensively on the genetics of PAH. He has reported the novel susceptive gene variant of Ring finger protein 213 gene (RNF213), which was predominant in East-Asia population, especially in Japan and Korea. RNF213 R4810K variant was identified as the independent poor-prognostic factor in patients with PAH. He created the animal model of RNF213-associated vasculopathy, and found that inflammatory chemokines were associated with the development of PAH. He holds a second-degree rank (2-dan) in Kyudo (Japanese archery), he likes fishing, and watching rugby games.

Yoshihiro Fukumoto

Kurume Univ. School of Medicine, Japan

Yoshihiro Fukumoto is Professor and Chairman of Cardiovascular Medicine in Kurume University School of Medicine, who is also a Fellow of JCC, JCS, AHA, and ESC. Dr. Fukumoto was awarded his medical degree from Kyushu University School of Medicine, and followed this with a PhD in coronary arteriosclerosis in Kyushu University, Fukuoka, Japan. After completing his residency, he spent time as a research fellow, clinical fellow, and clinician, working in both Japan and Brigham and Women's Hospital, Boston, MA, USA, before taking up the post of Associate Professor in the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan in 2011. Since July 2013, he has held the position of Professor and Chairman of Cardiovascular Medicine in the Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan. He is also a president of Japanese Society for Circulation Research (since October 2022), Japanese Pulmonary Circulation and Pulmonary Hypertension Society (since April 2024), Japanese Association of Cardiac Rehabilitation (since August 2024).

Zhi-Cheng Jing

Guangdong Cardiovascular Institute, China

Prof. Zhi-Cheng Jing is a Full Professor of Medicine and the Chairman of the Cardiovascular Medicine Department, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, the Vice President of Guangdong Academy of Medical Sciences. His clinical practice and research focus on Congenital Heart Disease and Pulmonary Vascular and Right Heart System. Prof. Jing obtained his M.D. degree in 1998 from Peking Union Medical College, and then participated in 2-year postdoctoral training at the Hospital Antoine Béclère with Professors Gerald Simonneau and Marc Humbert in Paris-Sud Université, France. He also received the training by World Heart Federation Emerging Leaders Programme and the American College of Cardiology Global Leadership Training program in 2014. He also is the associate Editor of HEART (the BMJ family journals), Senior Editor of JACC, the President of Guangdong Society of Cardiology. Prof. Jing led more than 100s International and National project / clinical trials on the genetics and basic / clinic research on pulmonary circulation and thrombosis, he is also the lead author on the National Clinical Guideline for Pulmonary Embolism and Pulmonary Hypertension organized by Chinese Society of Cardiology. He received almost all of most important National awards for Scientist-Physicians.
X

Chih-Hsin Hsu National Cheng Kung Univ., Taiwan

Educational Background

Visiting Scholar , University of Chicago Medical Center

PhD, Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan

Master Degree, Pulmonary Vascular Disease, University of Bologna, Bologna, Italy

MD, China Medical College, Taichung, Taiwan

Professional Career

2022- Professor, National Cheng Kung University

2023-, Deputy Superintendent, National Cheng Kung University Hospital

2020-2023 Medical Secretory, National Cheng Kung University Hospital

2019-2020 Deputy Superintendent, National Cheng Kung University Hospital Dou-Liou Branch

2004 Attending Physician, National Cheng Kung University Hospital

Research Field

Pulmonary Hypertension

Heart Failure

Heart Transplant Care

Critical Care

Post Resuscitation Care

X

Hiromi Matsubara Okayama Medical Center, Japan

Educational Background

Apr 1982- Mar 1988 MD; Okayama University Medical School

May 1988- Apr 1990 National Okayama Hospital, Department of Internal Medicine, Residency

May 1990- Apr 1993 National Cardiovascular Center, Department of Cardiology, Residency

Sep 2000 PhD; Okayama University Graduate School of Medicine and Dentistry

Professional Career

Okayama University Graduate School of Medicine and Dentistry, Department of Cardiology; Associate Professor (May 2000- Apr 2003)

National Hospital Organization, Okayama Medical Center, Department of Cardiology; Director (May 2003- Mar 2020, Department of Clinical Science; Director (May 2010- Mar 2019)

Entire Medical Departments; Director (Apr 2019 - Mar 2021), Vice President (Apr 2021 – active)

Research Field

clinical and physiological aspects of pulmonary hypertension

diagnosis and treatment of Group I PH

Interventional treatment of Group IV PH

Papers, Books, etc.

J Heart Lung Transplant. 2025. doi: 10.1016/j.healun.2025.10.031

Lancet Respir Med. 2025. doi: 10.1016/S2213-2600(25)00127-4

Circ Cardiovasc Interv. 2025. doi: 10.1161/CIRCINTERVENTIONS.125.016172

J Am Coll Cardiol. 2025;85:2270-2284. doi: 10.1016/j.jacc.2025.04.021

Clin Nucl Med. 2025;50:623-630. doi: 10.1097/RLU.0000000000005919

X

John Feenstra University of Queensland, Australia

Educational Background

MBBS, University of Queensland, 1996

BMedSc (with Distinction), Physiology and Pharmacology, University of Queensland, 1995

FRACP, Royal Australasian College of Physicians, 2005

Transplant and Pulmonary Hypertension Fellowship, The Prince Charles Hospital, 2005

Professional Career

Thoracic and Sleep Disorders Physician; Pulmonary Hypertension Specialist, 2005-Present

Lead Physician, Pulmonary Vascular Disease Unit/QLTS, The Prince Charles Hospital, 2015-Present

Director, Wesley Pulmonary Hypertension Unit, Wesley Hospital, 2008-Present

Director, Pulmonary Hypertension Research Queensland, 2025-present

President, Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ), 2021-Present

Senior Lecturer in Medicine, University of Queensland, 2006–Present

Research Field

Phase 1 to 4 Clinical Trials

Clinical trials in Groups 1 to 4

Exercise in PHT and exercise MRI

Papers, Books, etc.

Kearney K et al. (incl. Feenstra J). Impact of left heart disease risk factors on outcomes in PAH therapy. Chest. 2024;165(4):967–977.

Feenstra J et al. Effectiveness of epoprostenol in PAH: findings of an Australian retrospective chart review. Intern Med J. 2020;50(11):1377–1384.

Anderson J et al. (incl. Feenstra J). Retrospective Validation of the REVEAL 2.0 Risk Score with the ANZ PH Registry. Chest. 2020;157(1):162–172.

Scalia GM et al. (incl. Feenstra J). ePLAR – echocardiographic pulmonary to left atrial ratio: a novel parameter to differentiate pre- and post-capillary PH. Int J Cardiol. 2016;212:379–386.

H-index: 10. ORCID: 0009-0006-2840-9272. Full publication list available on request.

X

Keiko Yamauchi-Takihara Osaka Univ., Japan

Educational Background

She was a Vice-President of Japanese Pulmonary Circulation and Pulmonary Hypertension Society (JPCPHS) during 2015-2021. She graduated from Nagasaki University School of Medicine and obtained her Ph.D. from Osaka University Graduate School of Medicine.

Professional Career

From 1987, she worked at The Center for Cardiovascular Research, The Toronto Hospital, and since 1990, conducted research on signal transduction of cytokines and growth factors in cardiac myocytes at the Department of Cardiology, Osaka University Graduate School of Medicine.

She was appointed as Vice-President of Osaka University in 2014, and also worked as a Trustee of National Cerebral and Cardiovascular Center (2018-2024) and an Auditor of National Institute for Quantum Science and Technology, Japan (2020-2024).

Research Field

Although she has a longstanding interest in genetics and biological mechanisms of the development of cardiomyopathy, her research interests include pulmonary circulation and cardiopulmonary interrelations from the viewpoints of genetics and inflammation

Papers, Books, etc.

Over 100 reviewed basic and clinical research papers;

Successful treatment of severe combined post- and pre-capillary pulmonary hypertension in a patient with idiopathic restrictive cardiomyopathy. Pulm Circ. 2018 Jul-Sep;8(3)

Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2677-86. doi: 10.1073/pnas.1424774112.

The challenge of the "estrogen paradox" in pulmonary arterial hypertension. Circ J. 2013;77(8):1992-3.

Pulmonary arterial hypertension associated with chronic active Epstein-Barr virus infection. Intern Med. 2011;50(2):119-24.

X

Kuo Yang Wang China Medical Univ. Hospital, Taiwan

Educational Background

1979/07 MD. NATIONAL DEFENSE MEDICAL UNIVERSITY

1995/07-1997/07 -Post-doctoral fellowship, Hospital of the University of Pennsylvania, USA

2015/02 & /06 -Master class of Pulmonary Vascular Disease, Bologna University Hospital, Bologna, Italy

Professional Career

2018/12- Director, Center for PH and PVD, CMUH, Taichung, Taiwan

2015/04-2027/04 -Chairperson, Taiwan Pulmonary Hypertension Association (TPHA)

Research Field

Pulmonary hypertension including clinical and genetic studies

Papers, Books, etc.

Pulmonary hypertension publication in recent 5 years

Liang K-W, Chang S-K, Chen Y-W, Tsai W-J, Wang K-Y*(corresponding author). A cluster of heritable pulmonary arterial hypertension cases in a family with all three siblings carrying the same novel AQP1 c.273C>G variant-a case report. Pulm Circ. 2023;e12211. https: //doi.org/10.1002/pul2.12211

I Hsin Tai, Tsung-Cheng Shyu, Kai-Sheng Hsieh, Ke-Wei Chen, Wan-Jane Tsai, Kuo-Yang Wang*(corresponding author). Case report: The impact of percutaneous atrial septal defect closure in pulmonary hypertension with co-existing cor triatriatum sinister and multiple cardiac comorbidities. Front. Cardiovasc. Med., 07 September 2022 Sec. Cardiovascular Therapeutics https://doi.org/10.3389/fcvm.2022.913391

Kae-Woei Liang, Sheng-Kai Chang, Yu-Wei Chen, Wei-Wen Lin, Kuo-Yang Wang*(corresponding author). Whole exome sequencing of patients with primary pulmonary arterial hypertension in central Taiwan. Front Cardiovasc Med. 22 June 2022, doi: 10.3389/fcvm.2022.911649

Liang KW, Wei HJ, Wang KY*(corresponding author). Sustained hemodynamic and clinical improvements for a patient with idiopathic pulmonary arterial hypertension over 1.5 years after balloon atrial septostomy: a case report. Front Cardiovasc Med. 2022 Apr 7;9:868123. doi:10.3389/fcvm.2022.868123. eCollection 2022

X

Nick H. Kim UCSD, USA

Educational Background

College: Harvard University, 1989, A.B. (Magna Cum Laude, Biology)

Medical School: University of Chicago Pritzker School of Medicine, 1994, M.D.

Internship: University of Chicago, Internal Medicine, 1994-1995, 1996-1998

Residency: University of California San Francisco, Anesthesiology, 1995-1996

Fellowship: University of California San Diego, Pulmonary and Critical Care Medicine, 1998-2001

Professional Career

Faculty at UCSD since 2001. Fellowship program director 2009-2017. Currently, Professor of Medicine in the Division of Pulmonary, Critical Care, Sleep Medicine, & Physiology. Section Chief of Pulmonary Vascular Medicine. Medical Director of Pulmonary Thromboendarterectomy Program.

Research Field

Evaluation and treatment of pulmonary arterial hypertension

Interventional and medical management of chronic thromboembolic disease

Perioperative management following pulmonary thromboendarterectomy

Balloon pulmonary angioplasty for chronic thromboembolic disease

Clinical trials in pulmonary hypertension

Papers, Books, etc. presented or published by your name

As of Nov 2025: 132 peer-reviewed publications on pulmonary hypertension including, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Lead author for the 5th, 6th, and 7th World Symposium on Pulmonary Hypertension task force on “Chronic Thromboembolic Pulmonary Hypertension”. 4th World Symposium on Pulmonary Hypertension task force member: “Endpoints and Clinical Trial Design in PAH” and “Interventional and Surgical Modalities of Treatment in PH”.

X

Samuel G. Rayner University of Washington, USA

Educational Background

Macalester College, B.A., Biology (cum laude), 2006

University of Minnesota Medical School, M.D., 2011

Residency: Internal Medicine, University of Washington, 2011–2014

Fellowship: Pulmonary, Critical Care & Sleep Medicine, University of Washington, 2015–2018

Professional Career

Assistant Professor of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine, University of Washington. Principal Investigator of an NIH-funded pulmonary vascular biology laboratory. Medical Director of the UW Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program and Associate Director of the UW Hereditary Hemorrhagic Telangiectasia (HHT) Center.

Research Field

In vitro modeling of pulmonary arterial hypertension using bioengineered vascular platforms

Hemodynamic forces and pulmonary endothelial dysfunction

Translational multi-omics in pulmonary arterial hypertension

Diagnosis and management of chronic thromboembolic pulmonary hypertension

Papers, Books, etc.

Author of 44 peer-reviewed publications spanning pulmonary vascular disease, vascular biology, and related fields. Selected highlights:

Rayner SG et al. Multiphoton-guided Creation of Complex Organ-specific Microvasculature. Adv Healthc Mater. 2021.

Rayner SG et al. Zone of Uncertainty in Pulmonary Arterial Wedge Pressure Measurement. Am J Respir Crit Care Med. 2024.

Hirsch K*, Mandrycky CJ*, Kwan I, …Rayner SG. Endothelial Responses to Shear Stress and Pressure in PAH. bioRxiv. 2025 (under review).

X

Shigetoyo Kogaki Osaka General Medical Center, Japan

Educational Background

1982-1988: Osaka University Graduate School of Medicine

Professional Career

2018- : Director, Department of Pediatrics and Neonatology, Osaka General Medical Center

2003-2018: Assistant Professor, Department of Pediatrics, Osaka University Graduate School of Medicine

2002-2003: Pediatrics-in-chief, Department of Pediatrics, Ikeda Municipal Hospital

1999-2002: Research Fellow, Department of Vascular Biology, Institute of Child Health, University Collage of London

Research Field

Pediatric Pulmonary Circulation and Pulmonary Hypertension

Pediatric Cardiomyopathy and Heart Failure

Congenital Heart Disease

Papers, Books, etc.

Pharmacological Treatment Practices for Patients with Congenital Heart Disease and Pulmonary Hypertension in Japan: Insights from the Japanese Association of Congenital Heart Disease Registry (JACPHR). Am J Cardiol. 2025; 257:18-25.

Current Circumstances Regarding End-of-Life Among Adult Congenital Heart Disease Patients in Japan. Circ J. 2024; 88:640-641.

X

Shozaburo Doi Tokyo Healthcare Univ., Japan

Educational Background

1976 – 1978 Premedical Course, Tokyo Medical and Dental University, Chiba, Japan

1978 – 1982 M.D., Tokyo Medical and Dental University, Tokyo, Japan

2000 Ph.D. (Doctor of Medicine), Tokyo Medical and Dental University, Tokyo, Japan

Professional Career

1991 Board certified in Pediatrics, Japanese Pediatric Society

2011 Board certified in Pediatric Cardiologist, Japanese Society of Pediatric Cardiology and Cardiac Surgery

2011 Board certified in PALS provider, American Heart Association

Research Field

Japanese Medical Specialty Board and Instructor of Pediatrics

Specialty Board of Pediatric Cardiology

Honorary fellow of Japanese Society of Pediatric Cardiology and Cardiac Surgery

Honorary fellow of Japanese Pulmonary Circulation and Pulmonary Hypertension Society

Papers, Books, etc. presented or published by your name

Implantable Cardioverter Defibrillator for Primary Prevention in Children With Arrhythmogenic Right Ventricular Cardiomyopathy: A Case Series. Cureus. 2025 Jan 10;17(1):e77253

Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries. J Clin Med. 2026 Jan 30;15(3):1087. doi: 10.3390/jcm15031087

X

Stephan Rosenkranz Univ. of Cologne, Germany

Educational Background

Prof. Dr. med. Stephan Rosenkranz completed his Doctoral dissertation at Justus-Liebig-Universität Gießen, Gießen, Germany; a Post-doctoral fellowship at Harvard Medical School, Boston, Massachusetts, USA; and a residency and research fellowship at the Klinik III für Innere Medizin (Dept. of Cardiology), University of Cologne, Germany.

Professional Career

Prof. Dr. med. Stephan Rosenkranz currently holds the posts of Chair, Cologne Cardiovascular Research Center (CCRC); Full Professor of Cardiology (“Cardiopulmonary interaction”), University of Cologne; Head of Expert Center on Pulmonary Hypertension; Associate editor of European Journal of Heart Failure, Cardiovascular Research, Current Heart Failure Reports; and as a reviewer for numerous scientific journals, including Journal of the American Medical Association, Lancet, European Heart Journal.

Research Field

Prof. Dr. med. Stephan Rosenkranz has experience in numerous clinical trials in the field of heart failure and pulmonary hypertension (phase I, II, III, IV) and is Head ("Principal Investigator") of the working group on "Molecular Cardiology," with a research focus of Signal transduction and pathobiological relevance of tyrosine kinases in cardiovascular disease.

Papers, Books, etc. presented or published by your name

Most recently: Rosenkranz S, Ghofrani HA, Hoeper MM, et al. Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials [published correction appears in J Heart Lung Transplant. 2025:S1053-2498(25)01764-4. doi: 10.1016/j.healun.2025.02.1679.].
J Heart Lung Transplant. 2025;44(2):135-146. doi:10.1016/j.healun.2024.08.018

X

Takahiro Hiraide Keio Univ., Japan

Educational Background

Medical Graduate 2006 – 2012 Doctor of Medicine Keio University School of Medicine, Tokyo, JAPAN

Doctoral Course 2017 – 2020 Doctor of Philosophy Keio University School of Medicine, Tokyo, JAPAN

Professional Career

Residency 2012 - 2014 Internal Medicine Keio University Hospital, Tokyo, JAPAN

Fellowship 2014 - 2017 Cardiology Yokohama Citizen’s Municipal Hospital Kanagawa, JAPAN

Research Fellowship 2017 - 2020 Cardiology Keio University School of Medicine, Tokyo, JAPAN

Postdoctoral Fellowship 2021 – Present Cardiology Keio University School of Medicine, Tokyo, JAPAN

Fellowship 2025 – Present Medical genomics National Cerebral and Cardiovascular Center, Osaka, JAPAN

Research Field

I have focused on understanding the molecular mechanisms of pulmonary hypertension, right ventricular dysfunction, cardiac hypertrophy, and vascular diseases. I have conducted extensive basic researches on developing new therapies for the treatment of pulmonary arterial hypertension (PAH) using gene-editing technologies. My current role as a clinical physician at Keio University Hospital allows me to combine clinical practice with my research endeavors.
My researches have been recognized with several awards, including the “Best Young Investigator’s Award” and “Outstanding Research Award” from the Japan Cardiovascular Society, the “Young Researcher Award” from the European Society of Cardiology Pulmonary Circulation and Right Ventricular Function Working Group, the “Moderated Poster Presentation Winner” from the European Society of Cardiology, the “Oral Presentation Award” at the 1st Asian Cardiovascular Symposium at Basic Cardiovascular Sciences held in the USA, and the “Best Young Investigator’s Award” at the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Conference.

Papers, Books, etc.

Hiraide T, Tsuda N, Momoi M, et al. CXCL12/CXCR4 pathway as a novel therapeutic target for RNF213-associated pulmonary arterial hypertension. Sci Rep. 2024;14:26604.

Hiraide T, Suzuki H, Momoi M, et al. RNF213-associated vascular disease: a concept unifying various vasculopathies. Life. 2022;12:555.

Hiraide T, Kataoka M, Suzuki H, et al. Poor outcomes in carriers of the RNF213 variant (p.Arg4810Lys) with pulmonary arterial hypertension. J Heart Lung Transplant. 2020;39:103–112.

Hiraide T, Kataoka M, Suzuki H, Aimi Y, Chiba T, Kanekura K, Satoh T, Fukuda K, Gamou S, Kosaki K. SOX17 mutations in Japanese patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2018;198:1231–1233.

Hiraide T, Teratani T, Uemura S, et al. Pulmonary arterial hypertension caused by AhR signal activation protecting against colitis. Am J Respir Crit Care Med. 2021;203:385–388.

X

Yoshihiro Fukumoto Kurume University School of Medicine, Japan

Educational Background

1991.3 Graduate from Kyushu University School of Medicine

1993.6-1995.5 Research Fellow, Cardiovascular Medicine, Kyushu University

1998.10-2001.11 Research Fellow, Brigham and Women’s Hospital, Harvard Medical School

2011.8-2013.6 Associate Professor, Cardiovascular Medicine, Tohoku University

2013.7-Present Professor and Chairman, Cardiovascular Medicine, Kurume University

Professional Career

Yoshihiro Fukumoto is Professor and Chairman of Cardiovascular Medicine in Kurume University School of Medicine, who is also a Fellow of JCC, JCS, AHA, and ESC. Dr. Fukumoto was awarded his medical degree from Kyushu University School of Medicine, and followed this with a PhD in coronary arteriosclerosis in Kyushu University, Fukuoka, Japan. He is a president of Japanese Pulmonary Circulation and Pulmonary Hypertension Society (since April 2024), Japanese Association of Cardiac Rehabilitation (since August 2024).

Research Field

General cardiology

Pulmonary circulation

Heart failure

atherosclerosis

Cardiac rehabilitation

Papers, Books, etc. presented or published by your name

Minatsuki S, Fukumoto Y, et al. Significance of diffusing capacity of the lungs for carbon monoxide on chronic thromboembolic pulmonary hypertension. Thorax. 2026:thorax-2025-223670.

Sugiyama Y, Fukumoto Y, et al. Utility of liver stiffness for the classification of portopulmonary hypertension in precapillary pulmonary hypertension. Int J Cardiol. 2025;429:133126.

Satoh T, Fukumoto Y, et al. Hypopituitarism Induced by Continuous Infusion of PGI2 Analogues: A Case Series and the Role of ACTH Screening and Hydrocortisone Treatment. Pulm Circ. 2025;15:e70116.

Yamashita J, Fukumoto Y, et al. Effects of pulmonary endarterectomy and balloon pulmonary angioplasty in older adults with chronic thromboembolic pulmonary hypertension: A sub-analysis of the CTEPH AC registry. Int J Cardiol Heart Vasc. 2025;60:101751.

Yamaji K, Fukumoto Y, et al. Catheter-based examination for pulmonary microcirculatory function in patients with pulmonary hypertension. PLoS One. 2024;19:e0312609.

X

Zhi-Cheng Jing Guangdong Provincial People’s Hospital, China

Educational Background

Prof. Jing obtained his M.D. Ph.D. degree in 1998 from Peking Union Medical College, and then participated in 2-year postdoctoral clinical fellow training at the Hospital Antoine Béclère with Professors Gerald Simonneau and Marc Humbert, in Paris-Sud Université, France. He also received the training by World Heart Federation Emerging Leaders Programme and the American College of Cardiology Global Leadership Training program in 2014.

Professional Career

Prof. Jing is the Chairman of the Cardiovascular Medicine Department, Guangdong Cardiovascular Institute. He also is the associate Editor of HEART (the BMJ family journals), Senior Editor of JACC, the President of Guangdong Society of Cardiology. Prof. Jing led more than 100s International and National project / clinical trials on the genetics and basic / clinic research on pulmonary circulation and thrombosis, he is also the lead author on the National Clinical Guideline for Pulmonary Embolism and Pulmonary Hypertension organized by Chinese Society of Cardiology. He received almost all of most important National awards for Scientist-Physicians.

Research Field

Cardiovascular Medicine

Congenital heart disease

Pulmonary Circulation

Papers, Books, etc. presented or published under your name

Clinical features and survival in Taksyasu's arteritis-associated pulmonary hypertension: a nationwide study. Eur Heart J. 2021;42(42):4298-4305.

Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension. J Am Coll Cardiol. 2022;79(15):1477-1488.

Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2024; 84(12):1092-1103.

Evaluation of recombinant human prourokinase for acute pulmonary embolism: A phase 2, randomized clinical trial. Med. 2026 Mar 30:101068.

sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension. Eur Respir J. 2026 Jan 22:2502367.